Cellomics and BD Sign License Agreement to Further Expand Availability of High Content Screening
November 09 2004 - 9:05AM
PR Newswire (US)
Cellomics and BD Sign License Agreement to Further Expand
Availability of High Content Screening PITTSBURGH, and SAN JOSE,
Calif., Nov. 9 /PRNewswire/ -- Cellomics, Inc., the creator of High
Content Screening (HCS), and global medical technology company BD
(Becton, Dickinson and Company), through its BD Biosciences unit,
announced today that they have entered into a non-exclusive,
worldwide patent license agreement. The agreement will provide BD
with Cellomics' core High Content Screening patent portfolio that
includes both broad claims to HCS technology and specific classes
of HCS assays such as cytoplasm-nuclear translocation,
characterization of cellular toxicity, and receptor
internalization. Financial details of the agreement were not
disclosed. "We are very pleased to be working with BD to further
expand the adoption and availability of high content screening
technology. Through licensing of our HCS patent portfolio, we are
seeking to enable customers to more effectively address complex
biological questions," commented William T. Sharp, Cellomics' Vice
President of Business Development. "With the recent acquisition of
Atto Bioscience, and our licensing of this intellectual property
from Cellomics, BD Biosciences extends our commitment to the area
of high-content cellular analysis and strengthens our considerable
capabilities in the area of live cell research that include
high-resolution imaging, flow cytometry and a broad array of
reagent systems," added Mark Lewis, Vice President of BD
Biosciences. "Completion of this second significant licensing
arrangement of our HCS patent portfolio with a global company like
BD confirms the value of our extensive intellectual property in
this critical area of drug discovery and reaffirms our intent to
facilitate the expansion of the HCS market via an aggressive
licensing and commercial strategy," stated Daniel J. Calvo,
Cellomics' President and CEO. About BD BD is a medical technology
company that serves healthcare institutions, life science
researchers, clinical laboratories, industry, and the general
public. BD manufactures and sells a broad range of medical
supplies, devices, laboratory equipment, and diagnostic products.
For the fiscal year ended September 30, 2004, BD reported revenues
of $4.935 billion. About BD Biosciences A business segment of BD,
BD Biosciences (http://www.bdbiosciences.com/) is one of the
world's largest businesses supporting the life sciences and is
organized into four units: Clontech, Discovery Labware,
Immunocytometry Systems, and Pharmingen. BD Biosciences provides
high-quality products and services to accelerate discovery and
diagnosis in the life sciences. About Cellomics Cellomics, Inc. is
automating drug discovery through a unique, cell-based assay
platform that addresses the needs of Drug Discovery and Systems
Biology groups by offering complete systems for High Content
Screening. Cellomics' proprietary HCSinstruments, software, and
assays are in use worldwide in pharmaceutical, biotechnology, and
academic institutions. This press release may contain certain
forward-looking statements (as defined under Federal securities
laws) regarding BD's performance, including future revenues,
products and income, or events or developments that BD expects to
occur or anticipates occurring in the future. All such statements
are based upon current expectations of BD and involve a number of
business risks and uncertainties. Actual results could vary
materially from anticipated results described, implied or projected
in any forward-looking statement. Factors that could cause actual
results to vary materially from any forward-looking statement
include, but are not limited to: competitive factors; pricing and
market share pressures; changes in interest or foreign currency
exchange rates; difficulties inherent in product development and
delays in product introductions; changes in regional, national or
foreign economic conditions; increases in energy costs;
fluctuations in costs and availability of raw materials and in BD's
ability to maintain favorable supplier arrangements and
relationships; and changes in healthcare or other governmental
regulation; issuance of new or revised accounting standards, as
well as other factors discussed in this press release and in BD's
filings with the Securities and Exchange Commission. We do not
intend to update any forward-looking statements to reflect events
or circumstances after the date hereof except as required by
applicable laws or regulations. DATASOURCE: BD (Becton, Dickinson
and Company); Cellomics, Inc. CONTACT: Colleen T. White, Corporate
Communications of BD, +1-201-847-5369, or ; Phil Vanek, Director of
Marketing, +1-301-340-7320, ext. 226, or , for BD; or Judy P.
Masucci, Ph.D., Director of Marketing of Cellomics, Inc.,
+1-412-770-2200, ext. 2353, fax, +1-412-770-2450, or Web site:
http://www.bdbiosciences.com/ http://www.bd.com/
Copyright